Liquidia Corporation
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Liquidia Corporation Liquidia Corporation (LQDA) is a biopharmaceutical company that develops, manufactures, and commercializes products addressing unmet needs in rare cardiopulmonary diseases, including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD); its core offerings center on YUTREPIA, an inhaled dry powder formulation of treprostinil, alongside investigational therapies such as L606, a liposomal sustained-release formulation of treprostinil licensed from Pharmosa Biopharm Inc., and references to related products like Yutopia for inhalation and generic treprostinil options, all leveraging proprietary PRINT particle engineering technology for precise drug particle production. Founded in 2004 and headquartered in Morrisville, North Carolina, the company operates primarily in the United States through wholly owned subsidiaries Liquidia Technologies, Inc. and Liquidia PAH, LLC, targeting patients with rare respiratory conditions via innovative drug delivery systems that enhance convenience and efficacy. Recent developments include a $67.5 million common stock financing in September 2024 comprising a public offering and private placement with Caligan Partners LP, plus a $32.5 million advance under a fifth amendment to its Revenue Interest Financing Agreement with HealthCare Royalty, bringing total non-dilutive funding to $100 million and extending the agreement term to 2031 while supporting YUTREPIA commercialization, pediatric trials, and L606 advancement ahead of expected 2025 launch post-FDA tentative approval for PAH and PH-ILD; third quarter 2025 results highlighted launch momentum for YUTREPIA and improved profitability.
Company News
Liquidia Corporation Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money on Your LQDA Investments
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
Liquidia shares surge 25% as settlement ends United Therapeutics litigation
United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%
Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday
This Biotech Stock Surges 37% on Patent Settlement. ‘Better Than the Best-Case Scenario.
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH
Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky
Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky
Liquidia (NASDAQ:LQDA) Shares Gap Up – Here’s Why
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Liquidia Corporation (LQDA)
LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law
LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law
LIQUIDIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the Firm
LIQUIDIA CORPORATION INVESTIGATION: LQDA Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights
LQDA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Liquidia Corporation
Liquidia Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Liquidia (LQDA)
Liquidia (NASDAQ:LQDA) Stock Price Down 6.1% After Analyst Downgrade
Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%